New Interview In Scrip New Interview In Scrip By matt.poulter|2021-09-13T09:05:21+00:00September 13th, 2021| Read More
Monument Therapeutics is delighted to announce the appointment of Dr Paula Moran to its Scientific Advisory Board Monument Therapeutics is delighted to announce the appointment of Dr Paula Moran to its Scientific Advisory Board By matt.poulter|2021-08-13T14:04:27+00:00August 12th, 2021| Read More
Monument Therapeutics is delighted to announce the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director Monument Therapeutics is delighted to announce the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director By matt.poulter|2021-08-13T14:00:29+00:00August 3rd, 2021| Read More
Digital brain biomarker company Monument Therapeutics raises £2.6 million Digital brain biomarker company Monument Therapeutics raises £2.6 million By matt.poulter|2021-08-13T14:02:02+00:00July 1st, 2021| Read More
Latent inhibition and its potential as a biomarker for schizophrenia By matt.poulter|2021-05-21T11:57:22+00:00May 21st, 2021| Read More
Richard Bungay Joins the Board as a Director Richard Bungay Joins the Board as a Director By matt.poulter|2021-05-21T12:11:24+00:00June 29th, 2017| Read More
Postoperative cognitive dysfunction: an acute approach for the development of novel treatments for neuroinflammation By matt.poulter|2021-05-25T20:00:41+00:00November 2nd, 2016| Read More
